Prohibiting Generic Drug Delays: Lower Prices, Greater Access
This act aims to prohibit pharmaceutical companies from paying other companies to delay the market entry of cheaper generic and biosimilar drugs. This means citizens can expect faster access to more affordable medications, potentially lowering healthcare costs and increasing the availability of important treatments.
Key points
Agreements where brand-name drug manufacturers pay generic drug manufacturers to delay market entry are prohibited.
The Federal Trade Commission (FTC) will enforce these rules, imposing significant financial penalties on companies that violate the law.
The goal is to increase competition in the pharmaceutical market, leading to lower drug prices for consumers.
Expired
Citizen Poll